Company intelligence / Profile preview

Locus Biosciences

Morrisville, North Carolina, United Stateslocus-bio.com ↗

Ownership: Private
Employees: ~80
Development stage: Phase 2

Overview

Completed first human clinical trial in early 2021 with a crPhage product targeting E. coli in the urinary tract. Initiated Phase 2 trial of LBP-EC01 for UTIs in mid-2022.

Therapeutic areas: OncologyImmunologyNeurologyInfectious Diseases
Modalities: Engineered bacteriophage treatmentsCRISPR-Cas3 enhanced bacteriophage (crPhage)
Industry: Biotech

Drug pipeline

9 assets

LBP-EC01

8 more assets in the full pipeline.

Request access →

Partnerships

Johnson & Johnson (Janssen Pharmaceuticals)BARDACARB-X

Beyond the preview

Go deeper on Locus Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Locus Biosciences.

Explore the full profile